Duygu Tosun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1746425/publications.pdf

Version: 2024-02-01

67	2,429	212478 28 h-index	45
papers	citations		g-index
80	80	80	4498
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
2	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.4	17
3	Age-dependent brain morphometry in Major Depressive disorder. Neurolmage: Clinical, 2022, 33, 102924.	1.4	5
4	Deep learning for Alzheimer's disease: Mapping large-scale histological tau protein for neuroimaging biomarker validation. NeuroImage, 2022, 248, 118790.	2.1	17
5	Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. European Journal of Hybrid Imaging, 2022, 6, 2.	0.6	8
6	Multiple Cortical to Striatal Accumulation Trajectories of Î ² -Amyloid. Neurology, 2022, 98, 695-696.	1.5	0
7	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry, 2022, 79, 464.	6.0	47
8	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. Biological Psychiatry, 2021, 89, 757-765.	0.7	41
9	Improvements in Functional Disability After Psychotherapy for Depression Are Associated With Reduced Suicide Ideation Among Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 557-561.	0.6	4
10	The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status. Alzheimer's and Dementia, 2021, 17, 866-887.	0.4	14
11	Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
12	The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. Journal of Alzheimer's Disease, 2021, 80, 991-1002.	1.2	9
13	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging, 2021, 1, 521-534.	5.3	64
14	Lower cerebral perfusion is associated with tau-PET in the entorhinal cortex across the Alzheimer's continuum. Neurobiology of Aging, 2021, 102, 111-118.	1.5	21
15	Network-constrained technique to characterize pathology progression rate in Alzheimer's disease. Brain Communications, 2021, 3, fcab144.	1.5	3
16	White matter changes in drug-naÃ-ve Parkinson's disease patients with impulse control & mp; probable REM sleep behavior disorders. Journal of the Neurological Sciences, 2021, 430, 120032.	0.3	3
17	Regional uptakes from earlyâ€frame amyloid PET and ¹⁸ Fâ€FDG PET scans are comparable independent of disease state. Alzheimer's and Dementia, 2021, 17, .	0.4	O
18	Identifying individuals with nonâ€AD coâ€pathologies: A precision medicine approach to clinical trials in sporadic AD. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
19	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Scientific Reports, 2021, 11, 23788.	1.6	16
20	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	4.9	94
21	Dataâ€driven biomarker approaches to disentangle mixed pathologies in AD. Alzheimer's and Dementia, 2020, 16, e037995.	0.4	0
22	Impact of hybrid supervision approaches on the performance of artificial intelligence for the classification of chest radiographs. Computers in Biology and Medicine, 2020, 120, 103699.	3.9	5
23	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€Sectional Study. Movement Disorders, 2020, 35, 833-844.	2.2	48
24	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	3.7	219
25	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiology of Aging, 2019, 82, 110-119.	1.5	11
26	Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration. Brain, 2019, 142, 460-470.	3.7	63
27	O4â€04â€01: WHAT CAN STRUCTURAL MRI TELL ABOUT A/T/N STAGING?. Alzheimer's and Dementia, 2019, 15, P1237.	0.4	5
28	Preserved Structural Network Organization Mediates Pathology Spread in Alzheimer's Disease Spectrum Despite Loss of White Matter Tract Integrity. Journal of Alzheimer's Disease, 2018, 65, 747-764.	1.2	21
29	Abnormal Cerebral Perfusion Profile in Older Adults with HIV-Associated Neurocognitive Disorder: Discriminative Power of Arterial Spin-Labeling. American Journal of Neuroradiology, 2018, 39, 2211-2217.	1.2	7
30	The Parkinson's progression markers initiative (PPMI) $\hat{a}\in$ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	1.7	330
31	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2018, 33, 1305-1311.	1.3	16
32	Telomere attrition is associated with declines in medial temporal lobe volume and white matter microstructure in functionally independent older adults. Neurobiology of Aging, 2018, 69, 68-75.	1.5	19
33	Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. American Journal of Geriatric Psychiatry, 2017, 25, 980-991.	0.6	26
34	Association between tau deposition and antecedent amyloid- \hat{l}^2 accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	3.7	93
35	O4â€01â€04: Association between Tau Deposition and Retrospective Amyloid Accumulation Rates in Early Symptomatic Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P332.	0.4	0
36	ICâ€Pâ€182: Association Between TAU Deposition and Retrospective Amyloid Accumulation Rates in Early Symptomatic Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P133.	0.4	0

#	Article	IF	Citations
37	Accelerating rates of cognitive decline and imaging markers associated with \hat{I}^2 -amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.5	42
38	Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. Alzheimer's and Dementia, 2016, 12, 977-986.	0.4	27
39	Cerebral amyloid is associated with greater white-matter hyperintensity accrual in cognitively normal older adults. Neurobiology of Aging, 2016, 48, 48-52.	1.5	32
40	Diagnostic utility of ASLâ€MRI and FDGâ€PET in the behavioral variant of FTD and AD. Annals of Clinical and Translational Neurology, 2016, 3, 740-751.	1.7	42
41	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. American Journal of Geriatric Psychiatry, 2016, 24, 126-135.	0.6	60
42	Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-I ² -Positive Subjects in the Alzheimer's Disease Continuum. Neurodegenerative Diseases, 2016, 16, 87-94.	0.8	35
43	IC-P-039: ApoE- $\hat{l}\mu4$ genotype by gender interactions in regional amyloid accumulation in Alzheimer's disease continuum. , 2015, 11, P34-P35.		0
44	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	1.7	32
45	P3-165: Local amyloid-b toxicity in large intrinsic brain networks in cognitively healthy elderly. , 2015, 11, P692-P693.		0
46	Cortical thickness and sulcal depth: insights on development and psychopathology in paediatric epilepsy. BJPsych Open, 2015, 1, 129-135.	0.3	15
47	Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly. Frontiers in Aging Neuroscience, 2015, 7, 221.	1.7	50
48	Preliminary Evidence of Increased Hippocampal Myelin Content in Veterans with Posttraumatic Stress Disorder. Frontiers in Behavioral Neuroscience, 2015, 9, 333.	1.0	40
49	IC-01-02: Local amyloid-b toxicity on large intrinsic brain networks in cognitively healthy elderly. , 2015, 11, P1-P2.		0
50	O2-09-02: ApoE-É $_{^{3}}$ 4 genotype by gender interactions in regional amyloid accumulation in the Alzheimer's disease continuum. , 2015, 11, P195-P195.		2
51	Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease. Cell Reports, 2015, 10, 359-369.	2.9	177
52	Multimodal $\langle scp \rangle MRI \langle scp \rangle$ $\hat{a} \in b$ ased imputation of the A $\langle i \rangle \hat{I}^2 \langle i \rangle$ + in early mild cognitive impairment. Annals of Clinical and Translational Neurology, 2014, 1, 160-170.	1.7	29
53	Emerging Î ² -Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
54	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. NeuroImage: Clinical, 2014, 4, 508-516.	1.4	59

#	Article	IF	CITATION
55	Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Annals of Neurology, 2013, 74, 188-198.	2.8	37
56	DT-01-04: Bimodal distribution of the brain beta-amyloid load in the Alzheimer's disease cognitive continuum: Rate of regional accumulation or speed of spatial spread. , 2013, 9, P843-P843.		2
57	Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2013, 8, e85443.	1.1	16
58	MRI patterns of atrophy and hypoperfusion associations across brain regions in frontotemporal dementia. Neurolmage, 2012, 59, 2098-2109.	2.1	14
59	Intelligence and cortical thickness in children with complex partial seizures. NeuroImage, 2011, 57, 337-345.	2.1	9
60	Relationship Between CSF Biomarkers of Alzheimer's Disease and Rates of Regional Cortical Thinning in ADNI Data. Journal of Alzheimer's Disease, 2011, 26, 77-90.	1.2	43
61	Effects of childhood absence epilepsy on associations between regional cortical morphometry and aging and cognitive abilities. Human Brain Mapping, 2011, 32, 580-591.	1.9	36
62	Spatial patterns of brain amyloid-Â burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134, 1077-1088.	3.7	97
63	Joint analysis of structural and perfusion MRI for cognitive assessment and classification of Alzheimer's disease and normal aging. Neurolmage, 2010, 52, 186-197.	2.1	33
64	Joint Independent Component Analysis of Brain Perfusion and Structural Magnetic Resonance Images in Dementia. , 2010, , .		0
65	Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging, 2010, 31, 1340-1354.	1.5	95
66	An integrated multimodality MR brain imaging study: Gray matter tissue loss mediates the association between cerebral hypoperfusion and alzheimer's disease., 2009, 2009, 6981-4.		8
67	Cortical surface reconstruction using a topology preserving geometric deformable model 0		11